Cytomx Therapeutics, Inc.

Abbvie Biotherapeutics Inc.

Olivia Jennifer Razo

Jason Gary Sagert

Daniel Robert Hostetter

Bryan Allen Irving

Jennifer Hope Richardson

Fiona A Harding

Paul Robert Hinton

Sherry Lynn La Porte

Shiming Ye

Clayton William White

Mengli Xiong

The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same

The disclosure describes methods of identifying a variant of a reference antibody with reduced immunogenicity as compared to the reference antibody. The disclosure further describes variants of a reference anti-TNF-&#x3b1; antibody having reduced immunogenicity as compared to the reference anti-TNF-&#x3b1; reference antibody.

Methods for identifying antibodies with reduced immunogenicity

Growing community of inventors

Newark, CA, United States of America

Olivia Jennifer Razo